Tumour necrosis factor inhibitors: Maximizing patient safety [4]

Rheumatology

Volumn 42, Issue 1, 2003, Pages 188-189

  Cairns, A P ^a   Taggart, A J ^a  

^a MUSGRAVE PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBIOTIC THERAPY; ARTHROPATHY; CLINICAL TRIAL; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; LETTER; LONG TERM CARE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INFECTION; RECEPTORS, TUMOR NECROSIS FACTOR; SAFETY MANAGEMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037238832     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg046     Document Type: Letter

References (10)

1. Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF. Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 1986;29:706-14.
2. Lipsky PE, van der Heijde DM, St Clair EW et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med 2000;343:1594-602.
3. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
4. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
5. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin Proc 2001;76:653-6.
6. Lee J-H, Gershon SK, Rockville MMB. Acute life-threatening histoplasmosis complicating the use of infliximab and etanercept. Arthritis Rheum 2001;44(Suppl.):319.
7. Belostocki KB, Leibowitz E, Tai K, Harrison MJ. Infections associated with etanercept treatment of rheumatoid arthritis: 2 years of experience in the 'real world'. Arthritis Rheum 2001; 44(Suppl.):725.
8. Estrach C, Moots RJ, Andrews S, Williams D, Sykes HR, Dawson JK. High incidence of pneumonia in patients on anti-TNF-α therapy. Rheumatology 2002;41(Suppl. 1):232.
9. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. Ulster Med J 2002;71:in press.
10. National Institute for Clinical Excellence. NICE technology appraisal guidance, No. 36. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. London: National Institute for Clinical Excellence, 2002.